The original version of this article unfortunately contained a mistake. Due to a typesetting error ‘sorafenib pretreated’ was changed to ‘sorafenibpretreated’ throughout the article. The correct spelling is ‘sorafenib pretreated. There were also minor errors in Fig. 1 and Fig. 3. The original article has been corrected
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression (British Journal of Cancer, (2021), 125, 2, (190-199), 10.1038/s41416-021-01334-9) / Decaens, T.; Barone, C.; Assenat, E.; Wermke, M.; Fasolo, A.; Merle, P.; Blanc, J. -F.; Grando, V.; Iacobellis, A.; Villa, E.; Trojan, J.; Straub, J.; Bruns, R.; Berghoff, K.; Scheele, J.; Raymond, E.; Faivre, S.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 125:3(2021), pp. 465-465. [10.1038/s41416-021-01403-z]
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression (British Journal of Cancer, (2021), 125, 2, (190-199), 10.1038/s41416-021-01334-9)
Villa E.;
2021
Abstract
The original version of this article unfortunately contained a mistake. Due to a typesetting error ‘sorafenib pretreated’ was changed to ‘sorafenibpretreated’ throughout the article. The correct spelling is ‘sorafenib pretreated. There were also minor errors in Fig. 1 and Fig. 3. The original article has been corrected
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41416-021-01403-z.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
222.37 kB
Formato
Adobe PDF
|
222.37 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
